一种用于诊断疫苗诱导免疫性血栓性血小板减少症的新型流式细胞术促凝血检测
本研究开发了一种基于流式细胞术的促凝血血小板检测,通过将患者血浆与供者全血在蛋白酶激活受体-1激动剂存在下孵育,以GSAO和P-选择素为标志物诊断VITT。在47例疑似VITT的开发队列中,ELISA阳性患者血浆显著增加促凝血血小板反应;在99例VITT验证队列中,该检测识别了93%的VITT病例,包括ELISA阴性和5-羟色胺释放试验阴性的患者。患者血浆诱导的FcγRIIa依赖性促凝血反应可被肝素和IVIg抑制,该检测已被纳入国家诊断流程。
要点
- 流式促凝血血小板检测在99例VITT验证队列中识别了93%的病例。
- 该检测可识别ELISA阴性和5-羟色胺释放试验阴性的VITT患者。
- 患者血浆诱导的促凝血反应可被肝素和静脉注射免疫球蛋白抑制。
核心结论
- 患者血浆诱导的FcγRIIa依赖性促凝血反应,且可被肝素和IVIg抑制,高度提示VITT,由此形成了一种敏感且特异的检测,并已被采纳为国家诊断流程的一部分,用于识别具有血小板激活抗体的疫苗接种者。
研究设计与样本
- 研究纳入经PF4/肝素ELISA筛查后转诊进行确诊性功能学VITT检测的连续患者,开发队列47例疑似VITT患者,验证队列99例经临床病理学裁定确定的VITT患者。
主要发现
- 在47例疑似VITT的开发队列中,ELISA阳性患者(n=23)的血浆显著增加促凝血血小板反应,而健康供者(n=32)或未发生VITT的ChAdOx1 nCoV-19疫苗接种者(n=24)的血浆未显著增加该反应。
- 在99例VITT验证队列中,促凝血流式细胞术识别了93%的VITT病例,包括ELISA阴性和5-羟色胺释放试验阴性的患者。
- 静脉注射免疫球蛋白和磺达肝癸钠的体外效应与患者中观察到的临床反应趋势一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe prothrombotic complication of adenoviral vaccines, including the ChAdOx1 nCoV-19 (Vaxzevria) vaccine. The putative mechanism involves formation of pathological anti-platelet factor 4 (PF4) antibodies that activate platelets via the low-affinity immunoglobulin G receptor FcγRIIa to drive thrombosis and thrombocytopenia. Functional assays are important for VITT diagnosis, as not all detectable anti-PF4 antibodies are pathogenic, and immunoassays have varying sensitivity. Combination of ligand binding of G protein-coupled receptors (protease-activated receptor-1) and immunoreceptor tyrosine-based activation motif-linked receptors (FcγRIIa) synergistically induce procoagulant platelet formation, which supports thrombin generation. Here, we describe a flow cytometry-based procoagulant platelet assay using cell death marker GSAO and P-selectin to diagnose VITT by exposing donor whole blood to patient plasma in the presence of a protease-activated receptor-1 agonist. Consecutive patients triaged for confirmatory functional VITT testing after screening using PF4/heparin ELISA were evaluated. In a development cohort of 47 patients with suspected VITT, plasma from ELISA-positive patients (n = 23), but not healthy donors (n = 32) or individuals exposed to the ChAdOx1 nCov-19 vaccine without VITT (n = 24), significantly increased the procoagulant platelet response. In a validation cohort of 99 VITT patients identified according to clinicopathologic adjudication, procoagulant flow cytometry identified 93% of VITT cases, including ELISA-negative and serotonin release assay-negative patients. The in vitro effect of intravenous immunoglobulin (IVIg) and fondaparinux trended with the clinical response seen in patients. Induction of FcγRIIa-dependent procoagulant response by patient plasma, suppressible by heparin and IVIg, is highly indicative of VITT, resulting in a sensitive and specific assay that has been adopted as part of a national diagnostic algorithm to identify vaccinated patients with platelet-activating antibodies.
引用
- Lee CSM, Liang HPH, Connor DE, et al. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Adv. 2022. PMID: 35359002. doi:10.1182/bloodadvances.2021006698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。